Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Jacob Steven Leach net worth and biography

Jacob Leach Biography and Net Worth

EVP of DexCom

Jacob (“Jake”) Leach is Executive Vice President and Chief Technology Officer at Dexcom.

He is responsible for the leadership of scientific research, engineering, product development, and project management. Jake oversees the development of next generation products and leads a large organization of amazing people. His teams are responsible for delivering best in class glucose monitoring technology paired with an exceptional user experience.

Jake joined Dexcom in March 2004 to lead development of sensor electronics which were part of the first generation Dexcom system. Jake has since served in various leadership roles at Dexcom including Senior Vice President of R&D, Vice President of R&D and Senior Director of R&D.

Prior to Dexcom, Jake held positions in research and development at MiniMed and subsequently Medtronic Diabetes, focusing on the development of glucose sensing systems.

Jake holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles.

What is Jacob Steven Leach's net worth?: The estimated net worth of Jacob Steven Leach is at least $21.20 million as of September 9th, 2024. Mr. Leach owns 264,915 shares of DexCom stock worth more than $21,203,797 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Leach may own. Additionally, Mr. Leach receives a salary of $1,290,000.00 as EVP at DexCom. Learn More about Jacob Steven Leach's net worth.
How old is Jacob Steven Leach?: Mr. Leach is currently 46 years old. There are 6 older executives and no younger executives at DexCom. The oldest executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who is 66 years old. Learn More on Jacob Steven Leach's age.
What is Jacob Steven Leach's salary?: As the EVP of DexCom, Inc., Mr. Leach earns $1,290,000.00 per year. There are 2 executives that earn more than Mr. Leach. The highest earning executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who commands a salary of $3,230,000.00 per year. Learn More on Jacob Steven Leach's salary.
How do I contact Jacob Steven Leach?: The corporate mailing address for Mr. Leach and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Jacob Steven Leach's contact information.
Has Jacob Steven Leach been buying or selling shares of DexCom?: Jacob Steven Leach has not been actively trading shares of DexCom during the last quarter. Most recently, Jacob Steven Leach sold 746 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a transaction totalling $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. Learn More on Jacob Steven Leach's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 24 times. They sold a total of 248,077 shares worth more than $32,452,099.04. The most recent insider tranaction occured on November, 20th when EVP Sadie Stern sold 4,259 shares worth more than $318,275.07. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 11/20/2024.

Jacob Steven Leach Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Sell	746	$69.15	$51,585.90	264,915
3/12/2024	Sell	14,639	$134.41	$1,967,627.99	273,913
1/16/2024	Sell	3,978	$123.63	$491,800.14	262,499
4/20/2023	Sell	30,764	$125.00	$3,845,500.00	259,613
3/6/2023	Sell	18,144	$114.74	$2,081,842.56	281,089
7/30/2021	Sell	12,087	$476.70	$5,761,872.90
6/9/2021	Sell	22,755	$395.00	$8,988,225.00
6/11/2020	Sell	19,129	$376.76	$7,207,042.04
6/13/2019	Sell	5,099	$145.32	$740,986.68
9/28/2018	Sell	47,600	$143.95	$6,852,020.00	109,284
8/24/2018	Sell	20,577	$138.32	$2,846,210.64	109,455
5/8/2018	Sell	1,923	$84.95	$163,358.85	100,801
3/14/2017	Sell	21,317	$77.63	$1,654,838.71

Jacob Steven Leach Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $80.04

$75.47

$81.51

50 Day Range

MA: $74.53

$67.10

$81.01

2 Week Range

Now: $80.04

$62.34

$142.00

Volume

11,494,120 shs

Average Volume

3,910,878 shs

Market Capitalization

$31.26 billion

P/E Ratio

47.93

Dividend Yield

N/A

Beta

1.12

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.

Jacob Leach Biography and Net Worth

What is Jacob Steven Leach's net worth?

How old is Jacob Steven Leach?

What is Jacob Steven Leach's salary?

How do I contact Jacob Steven Leach?

Has Jacob Steven Leach been buying or selling shares of DexCom?

Who are DexCom's active insiders?

Are insiders buying or selling shares of DexCom?